Rod Rezaee, MD
- Division Chief, Otolaryngology, UH Ahuja Medical Center
- Director, Head and Neck Surgical Oncology and Reconstruction, UH Cleveland Medical Center
- Associate Professor of Otolaryngology, CWRU School of Medicine
- Professor of Otolaryngology, CWRU School of Medicine
- Specialty: Otolaryngology-Head and Neck
Location:UH Cleveland Medical Center
11100 Euclid Ave
Cleveland, OH 44106
- Call: 216-844-6000
Biography: Rod Rezaee, MD
Certifications & Memberships
- Otolaryngology - Head and Neck Surgery - American Board of Otolaryngology - Head and Neck Surgery
Fellowship | Head and Neck Surgery
Head and Neck Surgery - Mount Sinai Hospital (2001 - 2002)
Residency | Otolaryngology
Otolaryngology - The Ohio State University (1998 - 2001)
Internship | General Surgery
General Surgery - Mount Carmel Medical Center (1997 - 1998)
The Ohio State University College Of Medicine (1992 - 1996)
Cornell University (1992)
Rod Rezaee, MD, is the Director of Head and Neck Surgical Oncology and Reconstruction at the University Hospitals Ear, Nose and Throat Institute and an Associate Professor of Otolaryngology – Head and Neck Surgery in the Ear, Nose and Throat Institute at Case Western Reserve University School of Medicine. He is the Medical Director of the Surgical Oncology unit at UH Seidman Cancer Center and serves on the NCCN Thyroid Cancer Guidelines Committee as the representative of Case Comprehensive Cancer Center. He also serves on multiple national committees within the American Academy of Otolaryngology-Head and Neck Surgery and the American Head and Neck Society (AHNS), helping to improve the surgical, reconstructive and non-surgical care of head and neck cancer patients. Dr. Rezaee is a Governing Board Member of the Microvascular Reconstructive Surgery Committee within the AHNS. In addition, he serves as the Head and Neck Surgery Sub-group Leader for AAO-HNS Annual Meeting Planning Committee.
Dr. Rezaee has participated in numerous national clinical trials for head and neck cancer, evaluating the non-surgical management of HPV related diseases (RTOG 1016) and targeted therapies in the adjuvant setting (RTOG 0920). In addition, he participated in and supported accrual in the ECOG 3311 clinical trial evaluating surgical and non-surgical treatment of HPV oropharyngeal cancer and the Case 5315 clinical trial examining the intraoperative use of Cesium 131 for recurrent head and neck cancer. Dr. Rezaee is Site Primary Investigator for ECOG 3132, a clinical trial looking at post-operative randomization of radiotherapy with or without Cisplatin in patients with oral cavity squamous cell carcinoma with Tp53 sequencing. In collaboration with Dr. Aaron Weinberg and Dr. Ge Jin, Dr. Rezaee is also involved with the Case 4315 trial for investigation into the role of innate immune molecules in the development of head and neck cancers using a tissue bio-repository. In addition, Dr. Rezaee will be the Site Primary Investigator for two other head and neck clinical trials set to begin at University Hospitals/Seidman Cancer Center in 2021.
Related Blog Articles
When a blemish on Al Gizzi’s forehead turned out to be an invasive, potentially disfiguring cancer with cells also in his nose and cheek, a team of UH specialists collaborated on a complex surgery and innovative treatment that spared his nose.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Rod Rezaee did not disclose any Outside Relationships with Industry.